Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 466

1.

Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.

Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A.

J Hepatol. 2013 Oct;59(4):769-79. doi: 10.1016/j.jhep.2013.06.008. Epub 2013 Jun 17.

PMID:
23792028
2.

Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis.

Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B.

J Hepatol. 2013 May;58(5):956-61. doi: 10.1016/j.jhep.2013.01.005. Epub 2013 Jan 16.

PMID:
23333526
3.

Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.

Kazankov K, Rode A, Simonsen K, Villadsen GE, Nicoll A, Møller HJ, Lim L, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Vilstrup H, Frystyk J, Grønbæk H.

Scand J Clin Lab Invest. 2016;76(1):64-73. doi: 10.3109/00365513.2015.1099722. Epub 2015 Nov 7.

PMID:
26549495
4.

Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure.

Zheng SJ, Liu S, Liu M, McCrae MA, Li JF, Han YP, Xu CH, Ren F, Chen Y, Duan ZP.

World J Gastroenterol. 2014 Mar 7;20(9):2403-11. doi: 10.3748/wjg.v20.i9.2403.

5.

High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.

Lv Y, Wang W, Jia WD, Sun QK, Huang M, Zhou HC, Xia HH, Liu WB, Chen H, Sun SN, Xu GL.

Eur J Surg Oncol. 2013 Oct;39(10):1129-35. doi: 10.1016/j.ejso.2013.06.023. Epub 2013 Jul 31.

PMID:
23916473
6.

Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.

Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O.

Eur J Cancer. 2013 Nov;49(16):3442-9. doi: 10.1016/j.ejca.2013.06.002. Epub 2013 Jun 26.

PMID:
23810247
7.

Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.

Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G.

Crit Care Med. 2006 Oct;34(10):2561-6.

PMID:
16915112
8.

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.

Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, Chim AM, Yeung DK, Yu J, Chu WC, Wong VW.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1057-66. doi: 10.1111/apt.12091. Epub 2012 Oct 16.

9.

DR-70 immunoassay for the surveillance of hepatocellular carcinoma.

Lin SZ, Chen CC, Lee KC, Tseng CW, Lin HY, Chen YC, Lin HC.

J Gastroenterol Hepatol. 2012 Mar;27(3):547-52. doi: 10.1111/j.1440-1746.2011.06896.x.

PMID:
21883455
10.

Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma.

Atta MM, el-Masry SA, Abdel-Hameed M, Baiomy HA, Ramadan NE.

Clin Biochem. 2008 Oct;41(14-15):1131-9. doi: 10.1016/j.clinbiochem.2008.06.006. Epub 2008 Jun 20.

PMID:
18616935
11.

Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.

Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W.

Lancet Oncol. 2012 Aug;13(8):817-26. doi: 10.1016/S1470-2045(12)70233-4. Epub 2012 Jun 26. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
22738799
12.

Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.

Andersen MN, Abildgaard N, Maniecki MB, Møller HJ, Andersen NF.

Eur J Haematol. 2014 Jul;93(1):41-7. doi: 10.1111/ejh.12296. Epub 2014 Mar 20.

PMID:
24612259
13.

Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.

Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M.

Int Immunopharmacol. 2009 May;9(5):645-8. doi: 10.1016/j.intimp.2009.02.004. Epub 2009 Feb 26.

PMID:
19249390
14.

Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M.

Cancer Chemother Pharmacol. 2011 Aug;68(2):309-16. doi: 10.1007/s00280-010-1480-0. Epub 2010 Oct 22.

PMID:
20967544
15.

The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.

Ustaalioglu BB, Bilici A, Ercan S, Seker M, Orcun A, Gumus M.

Med Oncol. 2013 Jun;30(2):551. doi: 10.1007/s12032-013-0551-6. Epub 2013 Mar 28.

PMID:
23536001
16.

Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.

Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Hepatology. 2012 Oct;56(4):1371-9. doi: 10.1002/hep.25814.

PMID:
22535689
17.

Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.

Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1417-24.

PMID:
19950803
18.

Serum M65 as a biomarker for metastatic renal cell carcinoma.

Yildiz I, Sen F, Kilic L, Keskin S, Duranyildiz D, Bilgin E, Disci R, Ekenel M, Darendeliler E, Bavbek S, Basaran M.

Clin Genitourin Cancer. 2013 Sep;11(3):290-6. doi: 10.1016/j.clgc.2013.01.001. Epub 2013 Feb 4.

PMID:
23391372
19.

Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.

Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A.

Br J Cancer. 2015 Sep 1;113(5):756-62. doi: 10.1038/bjc.2015.227. Epub 2015 Aug 13.

20.

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T.

J Clin Oncol. 2009 Jul 10;27(20):3330-7. doi: 10.1200/JCO.2008.19.9919. Epub 2009 Jun 15.

PMID:
19528371

Supplemental Content

Support Center